论文部分内容阅读
目的观察艾迪注射液对乳腺癌患者血清血管内皮生长因子(VEGF)的影响,探讨其对乳腺癌的治疗作用。方法 46例乳腺癌患者随机分为对照组(单纯化疗)、实验组(化疗加艾迪注射液),每组23例。另收集30例健康人做为健康对照组。应用双抗体夹心ELISA法检测两组乳腺癌患者治疗前后血清VEGF水平变化。结果化疗前乳腺癌患者血清VEGF水平明显高于对照组(P<0.01),其水平与患者年龄、肿瘤大小、组织学分级无关(P均>0.05),与患者淋巴结转移、临床分期有关(P均<0.01)。新辅助化疗前乳腺癌患者血清VEGF明显高于健康对照组[(285.17±57.58)pg/ml vs(152.17±26.45)pg/ml,P<0.01];实验组治疗前、后血清VEGF水平分别为(289.30±61.50)、(210.13±52.12)pg/ml,差异有统计学意义(P<0.01);对照组治疗后血清VEGF水平与治疗前相比差异无统计学意义(P>0.05);实验组治疗后VEGF水平低于对照组[(210.13±52.12)pg/ml vs(261.46±54.29)pg/ml,P<0.01]。结论艾迪注射液可以降低乳腺癌患者血清VEGF水平,通过抑制肿瘤血管生成进而抑制肿瘤细胞的增殖、浸润及转移,从而发挥抗肿瘤作用,在乳腺癌辅助抗肿瘤治疗中起着重要作用。
Objective To observe the effect of Aidi injection on serum vascular endothelial growth factor (VEGF) in breast cancer patients and explore its therapeutic effect on breast cancer. Methods 46 cases of breast cancer were randomly divided into control group (chemotherapy alone) and experimental group (chemotherapy plus Aidi injection), with 23 cases in each group. Another 30 healthy people were collected as healthy control group. Serum VEGF levels in two groups of breast cancer patients before and after treatment were measured by double antibody sandwich ELISA. Results The serum level of VEGF in patients with breast cancer before chemotherapy was significantly higher than that in the control group (P <0.01). The level of VEGF was not related to the age, tumor size and histological grade (all P> 0.05), and was correlated with lymph node metastasis and clinical stage All <0.01). The serum level of VEGF in patients with neoadjuvant chemotherapy before breast cancer was significantly higher than that in healthy controls [(285.17 ± 57.58) pg / ml vs (152.17 ± 26.45) pg / ml, P <0.01] (289.30 ± 61.50) and (210.13 ± 52.12) pg / ml, respectively, with significant difference (P <0.01). There was no significant difference in serum VEGF level between the two groups after treatment (P> 0.05) The level of VEGF in the group after treatment was lower than that in the control group [(210.13 ± 52.12) pg / ml vs (261.46 ± 54.29) pg / ml, P <0.01]. Conclusion Aidi Injection can reduce the level of serum VEGF in breast cancer patients and play an antitumor effect by inhibiting tumor angiogenesis and inhibiting tumor cell proliferation, invasion and metastasis. It plays an important role in the auxiliary anticancer treatment of breast cancer.